![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
PUBLIC RELEASE DATE: 24-Oct-2013
[
]
ShareContact: Jim Fessenden
james.fessenden@umassmed.edu
508-856-2000
University of Massachusetts Medical School
High-impact research promises new method of studying neuropsychiatric diseases and mapping the relationship between brain activity and behavior
WORCESTER, MA University of Massachusetts Medical School Assistant Professor of Biochemistry and Molecular Pharmacology Gang Han, PhD, has received a $1.3 million EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant from the National Institute of Mental Health to develop light activated nanoparticles that can be used to image live brain tissue. These novel nanoparticles will form the basis of a new "optogenetic" tool that promises to help researchers map and decode previously inaccessible neural circuitry deep in the brain using near infrared light. Insights gleamed from this breakthrough technique will further our understanding of the relationship between neural circuit activity, behavior and neuropsychiatric diseases. The co-investigators on the grant include Carlos Lois MD, PHD, professor of neurobiology and Yang Xiang, PhD, assistant professor of neurobiology.
Understanding how the activities of certain neurons help to mediate behavior and influence disease is a prominent challenge in treating neuropsychiatric disorders. Optogenetics is an emerging technique hoping to address this challenge. It combines recent breakthroughs in both optics and genetics to allow scientists to stimulate the activity of individual neurons in animal models. However, current optogenetic tools rely on fiber optic probes to transmit light and stimulate neurons in vivo. Because these probes have to be surgically inserted into the brain and attached to a power source their practical use in animal models is greatly impeded.
With the EUREKA grant, Dr. Han proposes to develop a wireless optogenetic technique using key advances his lab has made in lanthanide-doped upconversion nanoparticles (UCNPs). The advantage of these nanoparticles is that they can be turned on using low power, tissue-penetrating, near infrared radiation that is then converted to higher energy, visible light that can be seen through deep tissue. This means that they can be activated remotely and safely inside living animal models to stimulate and observe particular neurons or neural circuitry without the need for surgery or restrictive probes. This would provide scientists an important new tool for mapping and understanding the complex interaction between particular neural pathways and behavior.
"This strategy offers a potential paradigm shift to achieve true 'wireless' control of neuron activation and deactivation," said Han. "The impact of such a new technique is impossible to overstate as it would allow us to study the relationship between neural circuitry activation and behavior, a possibility that even a few years ago was hard to image."
###
The EUREKA grant is part of a program by the National Institutes of Health to fund exceptionally innovative research projects enabling the establishment of novel concepts and approaches to solve important problems or open new areas for investigation.
About the University of Massachusetts Medical School
The University of Massachusetts Medical School (UMMS), one of five campuses of the University system, is comprised of the School of Medicine, the Graduate School of Biomedical Sciences, the Graduate School of Nursing, a thriving research enterprise and an innovative public service initiative, Commonwealth Medicine. Its mission is to advance the health of the people of the Commonwealth through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. In doing so, it has built a reputation as a world-class research institution and as a leader in primary care education. The Medical School attracts more than $240 million annually in research funding, placing it among the top 50 medical schools in the nation. In 2006, UMMS's Craig C. Mello, PhD, Howard Hughes Medical Institute Investigator and the Blais University Chair in Molecular Medicine, was awarded the Nobel Prize in Physiology or Medicine, along with colleague Andrew Z. Fire, PhD, of Stanford University, for their discoveries related to RNA interference (RNAi). The 2013 opening of the Albert Sherman Center ushered in a new era of biomedical research and education on campus. Designed to maximize collaboration across fields, the Sherman Center is home to scientists pursuing novel research in emerging scientific fields with the goal of translating new discoveries into innovative therapies for human diseases.
[
Share]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
PUBLIC RELEASE DATE: 24-Oct-2013
[
]
ShareContact: Jim Fessenden
james.fessenden@umassmed.edu
508-856-2000
University of Massachusetts Medical School
High-impact research promises new method of studying neuropsychiatric diseases and mapping the relationship between brain activity and behavior
WORCESTER, MA University of Massachusetts Medical School Assistant Professor of Biochemistry and Molecular Pharmacology Gang Han, PhD, has received a $1.3 million EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant from the National Institute of Mental Health to develop light activated nanoparticles that can be used to image live brain tissue. These novel nanoparticles will form the basis of a new "optogenetic" tool that promises to help researchers map and decode previously inaccessible neural circuitry deep in the brain using near infrared light. Insights gleamed from this breakthrough technique will further our understanding of the relationship between neural circuit activity, behavior and neuropsychiatric diseases. The co-investigators on the grant include Carlos Lois MD, PHD, professor of neurobiology and Yang Xiang, PhD, assistant professor of neurobiology.
Understanding how the activities of certain neurons help to mediate behavior and influence disease is a prominent challenge in treating neuropsychiatric disorders. Optogenetics is an emerging technique hoping to address this challenge. It combines recent breakthroughs in both optics and genetics to allow scientists to stimulate the activity of individual neurons in animal models. However, current optogenetic tools rely on fiber optic probes to transmit light and stimulate neurons in vivo. Because these probes have to be surgically inserted into the brain and attached to a power source their practical use in animal models is greatly impeded.
With the EUREKA grant, Dr. Han proposes to develop a wireless optogenetic technique using key advances his lab has made in lanthanide-doped upconversion nanoparticles (UCNPs). The advantage of these nanoparticles is that they can be turned on using low power, tissue-penetrating, near infrared radiation that is then converted to higher energy, visible light that can be seen through deep tissue. This means that they can be activated remotely and safely inside living animal models to stimulate and observe particular neurons or neural circuitry without the need for surgery or restrictive probes. This would provide scientists an important new tool for mapping and understanding the complex interaction between particular neural pathways and behavior.
"This strategy offers a potential paradigm shift to achieve true 'wireless' control of neuron activation and deactivation," said Han. "The impact of such a new technique is impossible to overstate as it would allow us to study the relationship between neural circuitry activation and behavior, a possibility that even a few years ago was hard to image."
###
The EUREKA grant is part of a program by the National Institutes of Health to fund exceptionally innovative research projects enabling the establishment of novel concepts and approaches to solve important problems or open new areas for investigation.
About the University of Massachusetts Medical School
The University of Massachusetts Medical School (UMMS), one of five campuses of the University system, is comprised of the School of Medicine, the Graduate School of Biomedical Sciences, the Graduate School of Nursing, a thriving research enterprise and an innovative public service initiative, Commonwealth Medicine. Its mission is to advance the health of the people of the Commonwealth through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. In doing so, it has built a reputation as a world-class research institution and as a leader in primary care education. The Medical School attracts more than $240 million annually in research funding, placing it among the top 50 medical schools in the nation. In 2006, UMMS's Craig C. Mello, PhD, Howard Hughes Medical Institute Investigator and the Blais University Chair in Molecular Medicine, was awarded the Nobel Prize in Physiology or Medicine, along with colleague Andrew Z. Fire, PhD, of Stanford University, for their discoveries related to RNA interference (RNAi). The 2013 opening of the Albert Sherman Center ushered in a new era of biomedical research and education on campus. Designed to maximize collaboration across fields, the Sherman Center is home to scientists pursuing novel research in emerging scientific fields with the goal of translating new discoveries into innovative therapies for human diseases.
[
Share]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-10/uomm-egt102413.php
Related Topics: Vma Miley Cyrus Brickyard 400
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.